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Soluble Ab oligomers contribute importantly to syn-
aptotoxicity in Alzheimer’s disease, but their dy-
namics in vivo remain unclear. Here, we found that
soluble Ab oligomers were sequestered from brain
interstitial fluid onto brain membranes much more
rapidly than nontoxic monomers and were recovered
in part as bound to GM1 ganglioside on membranes.
Ab oligomers bound strongly to GM1 ganglioside,
and blocking the sialic acid residue on GM1
decreased oligomer-mediated LTP impairment in
mouse hippocampal slices. In a hAPP transgenic
mouse model, substantial levels of GM1-bound
Ab42 were recovered from brain membrane fractions.
We also detected GM1-bound Ab in human CSF,
and its levels correlated with Ab42, suggesting its
potential as a biomarker of Ab-related membrane
dysfunction. Together, these findings highlight a
mechanism whereby hydrophobic Ab oligomers
become sequestered onto GM1 ganglioside and pre-
sumably other lipids on neuronal membranes, where
they may induce progressive functional and struc-
tural changes.
INTRODUCTION
The most prevalent neurodegenerative disorder, Alzheimer’s
disease (AD), impairs episodic declarative memory and execu-
tive function early in its clinical phase. Enhanced synapse loss,
particularly in the temporal and frontal cortices, helps distinguish
AD from normal brain aging (West et al., 1994) and serves as a
strong correlate of cognitive decline (Terry et al., 1991). Research
in many laboratories has provided extensive evidence that AD is
initially a disorder of selected synapses in which soluble, low
molecular weight (LMW) oligomers of amyloid b-protein (Ab)
can act as prime synaptotoxic agents (reviewed in Mucke and
Selkoe, 2012). In one example, mice expressing an APP muta-308 Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc.tion that causes AD in humans underwent rapid formation and
stabilization of Ab oligomers accompanied by profound synaptic
and neuronal loss in the absence of fibrillar amyloid plaques in
the cortex (Tomiyama et al., 2010). In light of numerous such
studies implicating a pathogenic role of soluble Ab oligomers
and the evidence that lowered Ab42 monomer levels in cerebro-
spinal fluid (CSF) represents the earliest biomarker for AD (Bate-
man et al., 2012; Craig-Schapiro et al., 2009; Fagan et al., 2009;
Golde et al., 2011; Morris and Selkoe, 2011), the search for such
oligomers in biological fluids, primarily in human CSF, has inten-
sified in recent years (Benilova et al., 2012). The recent report
that a phase 3 trial of the Ab-specific monoclonal antibody sola-
nezumab produced a small but significant cognitive benefit in
patients with mild AD (Doody, 2012, ANA, conference) has
made it even more critical to understand the earliest changes
in the economy of synaptotoxic Ab oligomers in the brain and
biological fluids. A few reports of the detection of apparent Ab
oligomers in CSF and plasma have appeared (Fukumoto et al.,
2010; Gao et al., 2010; Klyubin et al., 2008; Villemagne et al.,
2010); however, the interpretation of these reports has been
clouded by failure to define the precise oligomeric unit the
assays are detecting, an inability to exclude definitively the
detection of Ab monomers, and, in some cases, the lack of vali-
dating the assays on natural oligomers in biological samples.
In this context, we have systematically examined the steady-
state levels of LMW Ab oligomers in aqueous compartments of
the CNS, i.e., the brain interstitial fluid (ISF) and CSF of a well-
characterized mouse model of AD, the J20 hAPP transgenic
(tg) line (Mucke et al., 2000). While we readily detected mono-
mers, we failed to detect any substantial levels of LMW
(<35 kDa) Ab oligomers in the CNS fluid compartment using
several biochemical methods. We then hypothesized that due
to their increased hydrophobicity, Ab oligomers may bind to
cell membranes, preexisting Ab aggregates (in plaque-contain-
ing brains), or other hydrophobic surfaces much more rapidly
than monomers do. If so, this could help clarify potential mech-
anisms behind observations that Ab oligomers, but not mono-
mers, can exert synaptotoxicity (Gong et al., 2003; Klyubin
et al., 2005; Lacor et al., 2004; Lambert et al., 1998; Lesne´
et al., 2006; Shankar et al., 2007, 2008; Walsh et al., 2002), alter
tau and other cytoskeletal proteins (Go¨tz et al., 2001; Jin et al.,
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and induce other cytotoxic effects. To address this concept, we
quantified the in vivo half-life of microinjected Ab dimers versus
monomers in the ISF of healthy, wild-type (WT)mice usingmicro-
dialysis and ISF injections of synthetic Ab dimers and natural
oligomers isolated from human (AD) brain tissue. We followed
the fate of themicroinjected Ab and found that most of it became
tightly bound to endogenous GM1 ganglioside onmembrane ex-
tracts of the brains. In vitro binding assays indicated that Ab
dimers bind to GM1 ganglioside muchmore strongly thanmono-
mers. Masking the sialic acid residue on GM1 decreased Ab
oligomer-mediated LTP inhibition in WT mouse hippocampal
slices. Next, we examined brain membrane extracts of J20 tg
mice prior to plaque formation and recovered a significantly
higher level of endogenous Ab42 than Ab40 complexed with
GM1. The levels of GM1-Ab complexes obtained from brain
membrane extracts were proportional to the levels of diffusible
ISF Ab in young tg mice, suggesting that the formation of the
GM1-Ab complexesmay be a dynamic equilibrium. Finally, using
a sensitive immunoprecipitation (IP) technique, we discovered
low levels of GM1-bound Ab directly in human CSF, and its levels
correlated significantly with the CSF levels of Ab42. The implica-
tions of these findings for understanding the dynamic economy
of soluble Ab oligomers in the brain are discussed.
RESULTS
Steady-State Levels of LMWAbOligomers in CNS Fluids
Are Very Low or Undetectable
We initially assessed the levels of soluble Ab oligomers in the hip-
pocampal ISF and CSF. We define Ab oligomers here as soluble
LMW oligomers (dimers, trimers, tetramers, etc.) that remain in
the supernatant after high speed ultracentrifugation, as opposed
to high molecular weight, prefibrillar Ab aggregates that can
often be pelleted by ultracentrifugation. To obtain hippocampal
ISF, we performed in vivo microdialysis in awake, behaving
J20 tgmice usingmicrodialysis rates (0.2–0.4 ml/min) low enough
to allow ready recovery of soluble Ab (Cirrito et al., 2003; Hong
et al., 2011). CSFwas collected from the cisternamagna of anes-
thetized J20 mice (DeMattos et al., 2002), a method that, in
contrast to microdialysis, does not limit the recovery of soluble
molecules according to their size. Anti-Ab immunoprecipitates
of hippocampal ISF and CSF yielded the 4 kDa monomer and
a 5 kDa Ab-immunoreactive band migrating just above it but
no SDS-stable Ab dimers (which run at 6.5 kDa in these gels)
(Figures 1A and S1A available online). This apparent lack of Ab
oligomers in both tg ISF and CSF was not due to an inability of
our two polyclonal Ab antisera (AW8 [Hong et al., 2011] or
R1282 [Podlisny et al., 1998]) to immunoprecipitate oligomers,
as each effectively pulled down both the endogenous Ab dimers
present in Tris-buffered saline (TBS) extracts of 20-month-old tg
mouse brains and the synthetic WT Ab and disulfide-crosslinked
(Ab1-40 S26C)2 dimers (Shankar et al., 2008) (Figures 1A, S1A,
and S1B).
Next, we used a recently developed Ab oligomer-ELISA
(o-ELISA) that specifically recognizes natural Ab oligomers of
a wide range of sizes (dimers up to prefibrillar soluble oligo-
mers), but not Ab monomers, and detects small amounts(sensitivity% 6 pg/ml) of both synthetic and natural Ab oligomers
isolated from AD cortex (Yang et al., 2013). However, the
o-ELISA failed to detect any Ab oligomer signal in 3- and 20-
month-old tg ISF or 3-month-old tg CSF (Figure 1B). Using a
conventional ELISA that recognizes all Ab1-x species including
monomers, we confirmed that the tg mouse ISF and CSF indeed
contained ample amounts of Ab (Figure S1C). We excluded the
possibility thatmolecules in ISF or CSF interfere with the o-ELISA
technique, as spiking these CNS fluids with low amounts of pure
S26CAb dimers gave positive signals in the expected range (Fig-
ure 1B). We next eluted ISF of 3- and 20-month-old tg mice off a
Superdex 75 size exclusion chromatography (SEC) column and
subjected the resultant SEC fractions to a triplex ELISA that
can detect low-femtogram amounts of endogenous Ab38, Ab40,
and Ab42 (detection antibody: 6E10). Whereas SEC fractions
14–16 in which Ab monomers elute (i.e., the 4 kDa fractions)
gave abundant signals for all three Ab peptides, fractions 12
and 13 in which dimers elute (i.e., the 8 kDa fractions [Fig-
ure S1D]) yielded no detectable signal above background from
ISF at either age (Figures 1C and 1D). We confirmed that the
Ab triplex ELISA is capable of detecting SEC fractions of syn-
thetic dimers and monomers to commensurate degrees (Figures
S1D and S1E). Collectively, these results from multiple sensitive
biochemical assays—IP/WB, o-ELISA, and SEC followed by
ultrasensitive Ab triplex ELISA—suggest that steady-state levels
of LMW Ab oligomers in brain ISF or CSF of J20 tg mice are very
low and thus below the detection limits of the methods used
here.
Ab Oligomers Are Rapidly Sequestered Away from
Hippocampal ISF In Vivo
In light of this failure to detect significant amounts of LMW olig-
omers in brain ISF and CSF, we asked whether the half-life of Ab
oligomers in ISF is much shorter than that of monomers. We
acutely administered exogenous Ab dimers or monomers into
hippocampal ISF of behaving WTmice using a cannula attached
to the microdialysis probe. To distinguish the acutely adminis-
tered Ab from endogenous Ab, we injected Ab of human
sequence into ISF of WT mice and quantified the recovery of in-
jected human Ab in ISFmicrodialysates using Ab1-x ELISA, which
recognizes human but not mouse Ab. As our monomer source,
we used WT Ab1-40 monomers, and as the Ab dimer-rich source,
we used the S26C dimer, which was almost all dimeric and
stayed as such throughout the time of our in vivo microdialysis
(Figures S2A and S2B). We first empirically determined the con-
centrations of monomers and dimers that would allow equal
percentages of these species to flow across the microdialysis
membrane in vitro; the concentrations turned out to be 8 nM
for monomers and 40 nM for dimers (see Supplemental Experi-
mental Procedures; Figure S2C). In stark contrast to these
in vitro test-tube experiments in which the recoveries of Ab di-
mers and monomers were equivalent (Figure 2A), the in vivo re-
covery of the injected dimers in the ISF dialysate was <10% of
that of the injected monomers (Figure 2B). This large difference
in the relative recoveries of Ab dimers versus monomers
between in vitro (102% ± 11.4%) and in vivo (8.9% ± 2.8%)
microdialysis was highly significant (p < 0.0001) (Figure 2C).
Importantly, the disappearance of the injected Ab dimers fromNeuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc. 309
Figure 1. Ab Oligomers Are Not Detected in J20 hAPP tg Hippocampal ISF or CSF
(A) IP/WB of buffer (1.5%BSA in aCSF), 3-month-old tg hippocampal ISF andCSF, 20-month-old tg TBS extract, and synthetic Ab. IP: AW8 anti-Ab sera (1:100) or
preimmune AW8 sera (preIm, 1:100); WB: 3D6+2G3+21F12. D, dimer; M, monomer; MW, molecular weight. Representative of ten experiments.
(B) ISF of 3-month-old tg (n = 4 mice) and 20-month-old tg (n = 7 mice) and CSF of 3-month-old tg (n = 7 mice) were assayed using Ab o-ELISA. Sensitivity and
specificity of o-ELISA were tested using tg ISF and CSF spiked with low levels of synthetic Ab dimers or monomers and 20-month-old tg TBS extract and its
corresponding 3D6 Ab-immunodepleted sample.
(C and D) We loaded 250 ml hippocampal ISF from 3-month-old tg (C) and 20-month-old tg (D) onto Superdex 75 SEC column and resultant fractions were
subjected to 6E10 Ab triplex ELISA. Value = normalizedmean ±SEM; n = 3mice each. Dotted lines indicate where synthetic Ab dimers andmonomers were eluted
using the same SEC column. See also Figure S1.
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Ab dimers versus monomers in the ISF was not due to a general
limit on in vivo diffusion, nor did we obtain evidence of acute
perturbations of several non-Ab analytes in the respective micro-
dialysates (Figures S2D–S2F). The rapid disappearance of Ab
oligomers from brain ISF was confirmed using microinjection of
a second source of synthetic Ab dimers, namely, noncrosslinked
WT dimers (Figures S2H and S2I).
Ab Dimers Injected into Hippocampal ISF In Vivo Are
Principally Recovered in the Membrane Fraction as
Monomers Bound to GM1 Ganglioside
To follow the fate of Ab oligomers released into ISF, we injected
Ab dimers or monomers in low, endogenous amounts (320 pg)
into the hippocampal ISF of WT mice and immediately (<1 min)
sacrificed the mice for brain fractionation. The cytosolic/extra-
cellular (TBS) and membrane-associated (TBS with 1% Triton
X-100 [TBS-Tx]) fractions were promptly immunoprecipitated
for human Ab. A much higher percentage of the injected Ab
was immunoprecipitated from brain membrane fractions of the
dimer-injected mice than those of the monomer-injected mice
(Figures 2E and 2F). Surface biotinylation experiments in intact310 Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc.primary hippocampal neurons demonstrated the surface reten-
tion of Ab dimers, but not monomers, on the neuronal plasma
membrane; this surface binding occurred prior to lysing the bio-
tinylated cells (Figure S3A). The latter finding, together with the
rapid sequestration of Ab dimers away from ISF and to the brain
membrane fraction (Figure 2), suggests that Ab dimers bind
cellular membranes more avidly than monomers do and may
explain their very low or undetectable levels in CNS fluids (ISF
and CSF) at steady state.
In contrast to the in vitromicrodialysis experiments in which Ab
dimers remained stable as dimers for 24–36 hr (Figure S2B), the
Ab S26C dimers we injected into ISF in vivo were recovered as
reduced monomers in both the ISF microdialysates (1 hr after in-
jection) (Figure S2G) and the brain TBS and TBS-Tx fractions
(Figures 2E and 3A, see S26C 320 pg in vivo), except when a
much higher concentration of Ab S26C dimers was injected (Fig-
ure 3A, see S26C 320 ng in vivo). The conversion of the disulfide
crosslinked synthetic dimers to monomers when injected in vivo
could be explained by the brain providing a reducing environ-
ment. We therefore decided to isolate natural Ab dimers directly
from TBS cortical extracts of typical AD brains using SEC (Shan-
kar et al., 2008) and injected these human Ab dimers into the ISF
Figure 2. Ab Dimers Are Rapidly Sequestered Away from the Hippocampal ISF In Vivo to Bind Membranes
(A) (Ab1-40 S26C)2 dimers (40 nM) or Ab1-40 monomers (8 nM) in test tubes were microdialyzed at 0.1, 0.4, and 1.0 ml/min and the resulting microdialysates were
assessed using Ab1-x ELISA. n = 3 per group.
(B) Ab dimers or monomers were administered to living WT hippocampal ISF via a microdialysis cannula and postinjection ISF was collected at 0.4 ml/min for 1 hr
and analyzed for Ab1-x. n = 6 mice and n = 5 mice for monomer and dimer injected. *p = 0.0126 by two-tailed Student’s t test.
(C) In vivo recovery of injected dimers was 8.85% ± 2.81% of that of injected monomers (n = 5 pairs), in contrast to the in vitro paradigm (102% ± 11.4% [n = 3
pairs]). ***p < 0.0001 by two-tailed Student’s t test.
(D) Representative hourly monitoring of injected Ab monomers (blue triangle) or S26C Ab dimers (red circle) in ISF of WT mice before and after injection. Inset
shows values using a finer y scale for t = 2–5 hr.
(E) We injected 320 pg Abmonomers or S26C dimers into hippocampi of WT mice and their brain homogenates were immediately fractionated for R1282 Ab IP.
WB: 3D6+6E10. Both monomers and dimers were recovered as monomers in the TBS and TBS-Tx. Representative of four experiments.
(F) IP/WB quantification by ImageJ of n = 8 mice injected side by side with monomers or dimers. Proportion of Ab recovered in TBS-Tx versus TBS extracts after
Ab dimer injection was 23 ± 6.4-fold more than that of Abmonomer injection. ***p < 0.001 by two-way ANOVA, followed by Bonferonni post test. Value = mean ±
SEM. See also Figure S2.
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IP/WB from the brain homogenates as 4 and 5 kDaAbmonomers
(Figure 3A, see huAD TBS dimers in vivo). Almost all of the in-
jected Ab dimers (whether synthetic or from human brain) were
recovered in the TBS- and TBS-Tx-soluble extracts (Figure 3A),
and none was recovered in the TBS-Tx-insoluble pellets (data
not shown); the latter suggests that the injected dimers did not
accumulate into large insoluble aggregates during the short
time course of our experiment.
Intriguingly, whereas the injected Ab immunoprecipitated from
TBS extract ran at the size of monomers (4 kDa), the injected Ab
immunoprecipitated from TBS-Tx extract ran slightly higher as a
5 kDa species (Figure 3A, see S26C 320 pg in vivo and huAD TBS
dimers in vivo). Based on a prior report of a GM1 ganglioside-
bound form of human Abmonomer occurring as a 5 kDa species
in diffuse plaque-rich cortex of early AD or Down syndrome (DS)
cases (Yanagisawa et al., 1995), we probed the microinjected,
immunoprecipitated Ab species with the b-subunit of cholera
toxin (CTb), which specifically binds GM1 ganglioside (van Hey-
ningen, 1974). The immunoprecipitated 5 kDa Ab species recov-
ered from the TBS-Tx extract was reactive with CTb, indicating
that the Ab in the membrane fraction was bound to GM1 gangli-
oside (Figure 3B, first and fifth panels). High-resolution imagingof the hippocampal CA1 region of such WT mouse that received
in vivo Ab injection demonstrated that most of the retained Ab
was colocalizedwith endogenousGM1ganglioside (Figure S3B).
This result on brain sections suggests that the association of
GM1 with Ab occurs in vivo, that is, it can be seen without tissue
homogenization. Likewise, the above-mentioned surface bio-
tinylation of Ab on intact neurons (Figure S3A) supports this
conclusion. Importantly, we failed to recover the 5 kDa Ab spe-
cies when we performed the acute Ab injections into mice lack-
ing gangliotetraose gangliosides (i.e., with a disrupted gene for
GM2/GD2 synthase [Sheikh et al., 1999]), thus providing confir-
matory evidence that the 5 kDa Ab species is GM1 ganglioside-
bound Ab (Figure S3C). Interestingly, we did not observe a 5 kDa
GM1-bound Ab species when we spiked the Ab S26C dimers
ex vivo into postmortemWTmouse brain homogenates (Figure 3,
see 320 pg ex vivo), suggesting that the binding of Ab to endog-
enous GM1 on membranes required the intact environment of
the living brain. Furthermore, when we injected a high level of
Ab S26C in vivo, we recovered from the TBS-Tx fraction the Ab
S26C as intact dimers bound to GM1, namely, an 10 kDa
CTb-positive Ab species (Figures 3A and 3B, see 320 ng in vivo).
In light of the reported colocalization of PrPc to GM1 ganglio-
side on membranes (Sanghera et al., 2008; The´ry et al., 2009)Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc. 311
Figure 3. Ab Injected to WT Hippocampus
In Vivo Is Recovered from the Membrane-
Associated Fraction as Bound to GM1
Ganglioside
We injected 320 pg or 320 ng synthetic S26C Ab
dimers, huAD TBS dimers, or buffer (mock) to
anesthetized WT mice, then the brains were
immediately harvested for brain fractionation. The
in vivo injected brain fractions (TBS and TBS-Tx
extracts) or S26C Ab spiked ex vivo to extracts or
to buffer alone were immunoprecipitated for Ab
using R1282. WB: 3D6+6E10 for Ab (A) or CTb for
GM1 (B). Representative blots of n = 5, 3, 5, and 5
mice for 320 pg S26C, 320 ng S26C, mock, or
huAD TBS dimer injections, respectively. See also
Figure S3.
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oligomers (Chen et al., 2010; Laure´n et al., 2009), we asked
whether PrPc is required for the observed binding of the acutely
injected Ab to endogenous GM1 ganglioside. After similar acute
injection of a high amount (320 ng) of Ab S26C dimer into the hip-
pocampus of PrnP/ (null) mice, the animals were sacrificed
immediately for brain homogenization. We recovered Ab S26C
as bound to endogenous GM1 in PrnP null mice (Figure S3D)
in a manner indistinguishable from the injection results in WT
mice (Figure 3, 320 ng in vivo). Therefore, PrPc is not required
for the binding of Ab to GM1 ganglioside on brain membranes.
Ab Oligomers Preferentially Bind to GM1 Ganglioside
We next performed isothermal titration calorimetry (ITC), mea-
suring Ab binding to or incorporation into lipid membranes by
detection of concomitant heat release (Seelig, 2004). To use
ITC to quantitatively assess membrane binding in vitro, we
titrated suspensions of small unilamellar vesicles composed of
POPC/GM1 (9:1) into freshly prepared Ab S26C dimer solutions
and measured the observed heat release via ITC. Analysis of the
partition equilibrium revealed an apparent binding constant Kp of
the AbS26C interactionwithGM1 of10,000M1 per lipidmole-
cule bound (Figure 4A). As a control for the specificity of the inter-
action of Ab S26C with GM1, we repeated the ITC experiments
titrating suspensions of either pure POPC or POPC/SM (9:1)
into Ab S26C dimer solutions. These experiments yielded no
detectable heat release during the titration, indicating a lack of
interaction between Ab S26C and POPC alone or POPC plus
sphingomyelin (Figure 4A). Similar negative results were ob-
tained upon titrating POPC/GM1 into solutions of either WT
Ab40 monomer or Ab S26C solutions with reducing agent
(1% bME) present (i.e., monomers) (Figure 4B). These ITC exper-
iments suggest that the dimeric state of the Ab protein binds
GM1 much more avidly than the monomeric state and that the
monosialotetrahexosyl head group of GM1 may be necessary
for efficient Ab binding to lipid membranes, at least in vitro.
Blocking the GM1 Sialic Acid Moiety Prevents Ab
Oligomer-Mediated LTP Impairment
We asked whether the binding of Ab dimers to GM1 ganglioside
has functional consequences, that is, whether it plays a role in312 Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc.the known ability of the dimers to potently inhibit long-term
potentiation (LTP) (Li et al., 2011; Shankar et al., 2008). The sialic
acid of GM1 has been shown to be required for the in vitro bind-
ing of Ab to GM1 (Ariga et al., 2001; Choo-Smith et al., 1997;
McLaurin and Chakrabartty, 1996). We therefore asked whether
masking the sialic acid with CTb, which binds to the two terminal
sugars of GM1 including sialic acid (Merritt et al., 1994), may
interfere with the binding of Ab oligomers to GM1 in hippocampal
slices and thus reveal any functional consequences of the bind-
ing. At a dose (0.4 mM) at which CTb by itself caused a slight
decrease of LTP magnitude in WT mouse hippocampal slices
(140% ± 6%, n = 8; Figure 5A, blue circles), pretreatment with
CTb fully prevented the impairment of hippocampal LTP by sol-
uble S26C Ab dimers (153% ± 3%, n = 9, green triangles) (Fig-
ure 5). These data suggest that the binding of Ab oligomers to
GM1 ganglioside plays a required role in mediating Ab-induced
synaptic dysfunction.
Endogenous Ab, Particularly Ab42, Is Complexed to
GM1 Ganglioside on Membranes of Young hAPP
Transgenic Mice
We next asked whether endogenous Ab occurs in a complex
with GM1 ganglioside on brain membranes. Using an Ab anti-
serum (R1282), we immunoprecipitated the brain TBS-Tx ex-
tracts of 3-month-old J20 tg, 20-month-old J20 tg, or non-tg
littermate mice and found that the TBS-Tx extracts of the
plaque-free 3-month-old tg mice contained CTb-positive GM1-
bound Ab (Figure 6A). In contrast, the plaque-rich 20-month-
old tg contained very little GM1-bound Ab in the membrane
extract despite having far more total Ab (Figure 6A). We failed
to detect other brain lipids such as galactocerebroside (GCB)
or phosphatidylethanolamine (PE) in the Ab immunoprecipitates
of 3-month-old tg TBS-Tx (Figure S4B). Moreover, thin-layer
chromatography of the R1282 Ab immunoprecipitates showed
lack of enrichment in themajor brain lipids detectable by the lipid
dye primulin (Figure S4C), whereas the Ab immunoprecipitate of
the 3-month-old tg TBS-Tx (but not that of the non-tg) yielded a
CTb-positive spot (Figure S4D). Next, we took advantage of a
monoclonal antibody (4396C) specifically raised against GM1-
bound Ab isolated from membrane fractions of human brains
rich in diffuse plaques (Hayashi et al., 2004; Yanagisawa et al.,
Figure 4. Ab Dimers Bind to GM1 Ganglio-
side Much More Avidly than Ab Monomers
(A) Suspensions of POPC/GM1 (9:1), POPC/
sphingomyelin (SM) (9:1), or pure POPC small
unilamellar vesicles at 40 mM were titrated into
freshly prepared Ab S26C dimer solutions (15 mM)
and subsequent heat release was measured. The
hyperbolic shape of the titration curve in case of
POPC/GM1 (9:1) indicates a partition equilibrium of
Ab S26C dimers into the lipid membrane, while
titrations of POPC/SM (9:1) or pure POPC vesicles
yielded no detectable heat release.
(B) Titrating suspensions of POPC/GM1 (9:1) into
solutions containing WT Ab40 monomers or Ab
S26C with 1% bME present (i.e., reduced mono-
mers) yielded no detectable heat release during
the titration when compared to Ab S26C dimers.
Representative of three experiments each using
two different preparations of AbS26C and vesicles.
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nor GM1 alone (Figure S4A) but that it immunoprecipitates the
GM1-bound Ab complex from 3-month-old tg TBS-Tx, leaving
behind in the supernatant an Ab species that is not CTb positive,
as recovered by a subsequent R1282 IP (Figures 6B and S4A).
The 4396C immunoprecipitate from 3-month-old tg TBS-Tx con-
tained a CTb-positive 5 kDa Ab species (Figure 6B, lane 1) with a
characteristic cap-like shape akin to that of the 5 kDa Ab from
WT TBS-Tx that received in vivo Ab injection (Figures 2E
and 3). As in the R1282 Ab immunoprecipitates of 20-month-
old tg TBS-Tx (Figure 6A), 4396C brought down very low levels
of CTb-positive 5 kDa Ab from these old, plaque-rich animals
(Figures 6B). Using C-terminal-specific Ab antibodies for IP, we
found substantially more Ab42 than Ab40 to be GM1 ganglioside
bound, despite there being comparable levels of total Ab40 and
Ab42 recovered from the membrane extracts of 3-month-old tg
(Figures 6C and 6D). Collectively, these various findings in
J20 tg mice support the hypothesis that more hydrophobic Ab
species (oligomers > monomers; Ab42 > Ab40) are sequestered
onto neuronal membranes, primarily onto GM1 ganglioside.
In contrast to the Ab acute microinjection experiments in
3-month-old WT mice, where most of the exogenous Ab was
recovered as bound to GM1 ganglioside in the membrane
extracts (Figure 3), a smaller portion of endogenous Ab (5%–
30%) was recovered as bound to GM1 ganglioside in the
3-month-old J20 tg brains (Figures 6B and S4D). Further-
more, the higher recovery of endogenous GM1-bound Ab in
3-month-old tg brain (preplaque, high ISF Ab42) versus 20-
month-old tg brain (plaque-rich, low ISF Ab42) may be associated
with the levels of available ISF Ab at these two ages (Hong et al.,
2011). To assess whether it is predominantly the endogenous Ab
that is actively released into the ISF that binds GM1, we treated
the 3-month-old tg mice with Compound E, a strong inhibitor of
g-secretase that induces a rapid decline in brain ISF Ab (t1/2
of 2 hr) (Hong et al., 2011). Compound E decreased the levels
of GM1-bound Ab in the 3-month-old tg TBS-Tx in a manner
comparable to its reduction of ISF Ab levels (Figures 6E and
6F), suggesting that there is a rapid equilibrium between soluble
(ISF) and membrane-bound (TBS-Tx) pools of Ab. We confirmedthat Compound E had no effect on total GM1 levels in the brain
(data not shown). Collectively, all of the results in this section
suggest that newly generated Ab, and especially Ab42, upon
being released into the extracellular fluid (i.e., ISF), readily binds
to GM1 ganglioside on adjacent membranes, and this can
apparently occur early in the AD pathogenic process, i.e., before
plaques form. Finally, whereas we recover dimers in the 20-
month-old tg TBS-Tx, they do not seem to be associated with
GM1, as evidenced by the negative CTb blotting in the R1282
Ab immunoprecipitates (Figure 6A). The dimers that we observe
in the TBS-Tx extract of plaque-rich 20-month-old tg may not
necessarily be associated with membranes per se but may
represent Ab oligomers that are extracted from plaques during
tissue homogenization in TBS-Tx (Hong et al., 2011).
GM1-Bound Ab Is Detectable in Human CSF and
Correlates with CSF Ab42 Levels
Using the 4396C antibody that is specific for the GM1-Ab com-
plex (Figure S4A), we recovered a soluble GM1-bound Ab
species in cognitively normal human CSF (n = 10 samples), as
evidenced by positive reaction for Ab and GM1 (CTb+) at
the 4.5–5 kDa position (Figure 7A, 4396C IP/Ab WB first, then
stripped and blotted with CTb; Figure 7B, 4396C IP directly
blotted with CTb). The levels of GM1-bound Ab in human CSF
showed a significant direct correlation (r2 = 0.72) with levels of
Ab42 in the same CSF samples (Figures 7C and 7D) and to a
lesser but still significant degree (r2 = 0.49) with levels of Ab40
(Figure 7E).
DISCUSSION
Despite the extensive genetic and biochemical evidence for a
pathogenic role of soluble Ab oligomers in the most common
cognitive syndrome of late life, our understanding of the dy-
namics of Ab oligomers in the CNS in vivo is limited. To address
key mechanistic and biomarker-related questions of whether Ab
oligomers are present in biological fluids and the nature of their
dynamics, we first searched for oligomers in the two CNS
aqueous compartments, ISF and CSF, of tg mice that expressNeuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc. 313
Figure 5. Pretreatment of Hippocampal Slices with CTb Blocks Ab
Oligomer-Mediated LTP Inhibition
(A) S26C dimers (10 nM) alone blocked LTP induction (129% ± 6%, n = 12, red
inverted triangles) compared to vehicle alone (aCSF) (159% ± 6%, n = 12,
black squares). Whereas CTb (0.4 mM) alone slightly decreased LTP (140% ±
6%, n = 8, blue circles), it fully restored the S26C dimer-impaired hippocampal
LTP (153% ± 4%, n = 9, green triangles). n = slices.
(B) The effect of S26C alone versus S26C on slices pretreated with CTb is
compared. Value = mean ± SEM at 55 min of LTP induction. ***p < 0.0001 by
two-tailed Student’s t test.
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Rapid Sequestration of Soluble Ab Oligomers by GM1substantial levels of hAPP and undergo progressive AD-like
cerebral deposition of human Ab. Despite combining three sen-
sitive biochemical methods, IP-WB, o-ELISA, and SEC followed
by triplex ELISA, we failed to detect substantial levels of soluble
LMW (<35 kDa) Ab oligomers in hippocampal ISF or CSF of this
ADmousemodel. These results are consistent with two previous
ELISA reports that failed to detect Ab oligomers in human CSF
(Esparza et al., 2013; Yang et al., 2013), one of which used two
highly specific Ab o-ELISAs in samples of CSF from 90 humans
(including elderly subjects with either presymptomatic or early
clinical AD) (Yang et al., 2013). Based on these studies and the
current work, we conclude that the steady-state levels of LMW
Ab oligomers in the brain’s aqueous compartments are very
low (<0.02% of total CSF Ab levels) and thus below the detection
limits of the specific methods used here.
To explore this dearth of soluble oligomers mechanistically,
we performed in vivo Abmicroinjection experiments into the hip-
pocampal ISF of WT (plaque-free) mice and observed far lower
recovery of injected dimers than of injected monomers, raising
the hypothesis that soluble Ab dimers released into the extracel-
lular space are unlikely to remain very long in aqueous fluids. In
accord, their relative hydrophobicity appeared to drive the
sequestration of the dimers away from the extracellular fluid
and onto local membranes. A much higher proportion of the in-
jected dimers was recovered in the membrane (TBS-Tx) extract
than in the soluble (TBS) fraction of the brain. Surface bio-
tinylation experiments on intact hippocampal neurons and a
quantitative in vitro binding assay using isothermal calorimetry
likewise demonstrated that Ab oligomers bind membranes
muchmore avidly than Abmonomers do. We therefore conclude
that any newly generated and released Ab oligomers may be
rapidly sequestered from the extracellular fluid (ISF) onto plasma
membranes of surrounding cells in the brain parenchyma.
Inmimicking newly formedAboligomers in the brain, the in vivo
injected dimers rapidly became membrane bound, in contrast to
the monomers. Intriguingly, both synthetic dimers and natural
dimers isolated from human AD cortex that were injected at
low levels into WT mouse ISF were recovered in membrane ex-314 Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc.tracts as monomers bound to GM1 ganglioside, thus shifting
their electrophoretic migration to 5 kDa. This, along with the
ITC binding assays and the microinjection experiments in GM1
knockout (KO) mice, suggests a relative propensity for Ab dimers
to bind to GM1-containing lipids on membranes. This realization
led us to use pan-Ab, C-terminal-specific, and GM1-Ab-specific
antibodies to probe Ab species in a hAPP tg mouse model, and
we observed substantial levels of endogenous GM1-bound Ab,
in particular the Ab42 peptide, in the brain membrane fraction
at an early age (3 months), before plaques form in this model.
This result is reminiscent of an earlier study showing that Ab42
can be found associated with GM1 ganglioside in the brains of
AD and DS subjects who had abundant diffuse plaques but little
to no mature plaques or neurofibrillary tangles (Yanagisawa
et al., 1995). The disassociation of dimers to monomers (unless
given at high ng levels) seems to occur after the dimers bind to
membranes, as suggested by both the surface biotinylation
experiment in primary hippocampal neurons and the ITC. The
use of a covalently crosslinked form of Ab oligomers would be
insightful to further understand this process. In addition, it would
be interesting to measure the half-life and fate of oligomers in
brains already having very abundant Ab plaques, as we previ-
ously did with the monomers (Hong et al., 2011).
To date, we have failed to detect an enrichment of other brain
lipids bound to Ab in our assays, including certain phospholipids,
ceramides, and phosphosphingolipids that we probed for. More-
over, preliminary data using GM2/GD2 synthase KO mice sug-
gested a possible gene-dosage effect of GM1 in mediating the
sequestration of Ab dimers onto membranes: the less GM1 the
brain had, the lower the percent of injected Ab dimers we recov-
ered from the membrane fraction (data not shown). However,
caution is needed in using this mouse model, as these mice
now have robustly increased levels of GM3 and GD3 in the
CNS (Wu et al., 2001); GM3 has also been shown in vitro to
bind to and facilitate the aggregation of Ab (Ariga et al., 2001;
Grimm et al., 2012; Yahi et al., 2010; Yamamoto et al., 2005).
Given these confounding factors, we do not regard this GM1
KO model as ideal for the study of Ab effects. It is important to
emphasize that although our data using an array of techniques
uncover a preferential binding of Ab oligomers to GM1 ganglio-
sides and that this Ab-GM1 binding survives denaturation by
SDS and heat, there may well be other lipid targets to which
Ab binds. Lipidomic mass spectrometry is currently being pur-
sued to examine various lipid candidates. The key finding that
we can recover a GM1-Ab complex in fresh human CSF samples
suggests that the GM1-Ab complex exists in vivo in the human
brain (i.e., in the absence of tissue homogenization) and that it
reaches the CSF in small amounts. Likewise, immunohistochem-
istry of mouse brain sections after in vivo Ab injection showed
that the remaining injected Ab was principally colocalized with
endogenous GM1 ganglioside, again eliminating tissue homoge-
nization as an artifactual reason for this association. Finally, the
spiking of Ab oligomers into postmortem brain membrane ex-
tracts ex vivo failed to induce binding of the exogenous Ab to
endogenous GM1 gangliosides, suggesting that the formation
of the GM1-Ab complex we recover both in WT in vivo microin-
jection studies and in hAPP tg mice requires the environment
of the intact living brain.
Figure 6. Ab in Membrane-Bound Fraction
of Preplaque J20 tg Mice Is Associated
with GM1 Ganglioside
(A, B, C, and E) IP: as indicated, WB: 3D6+6E10+
266+2G3+21F12 for Ab or CTb for GM1. (A) R1282
Ab IP of 3-month-old tg, 20-month-old tg, or
non-tg littermate control TBS-Tx extracts. (B)
We first subjected 3-month-old tg and 20-month-
old tg TBS-Tx to 4396C IP, then the immunode-
pleted supernatants were subjected to R1282 IP.
Asterisk = GM1-Ab. Representative of three ex-
periments.
(C and D) 2G3 or 21F12 IP of 3-month-old tg and
littermate control TBS-Tx extracts. (D) Quantifica-
tion of total, GM1-bound or percentage GM1-
bound Ab in 3-month-old tg TBS-Tx pulled down
by 2G3 (Ab40) or 21F12 (Ab42). n = 6 mice.
(E and F) We injected 3-month-old tg with Com-
pound E or vehicle; 2.5 hr or 5 hr later, their brains
were harvested and their TBS and TBS-Tx extracts
were subjected to R1282 IP. (F) Quantification of
total or GM1-bound Ab recovered from TBS and
TBS-Tx with or without treatment. n = 4, 3, and 4
mice for vehicle, 2.5 hr, and 5 hr Compound E
treated, respectively. (D and F) Value = mean ±
SEM. *p < 0.05 or **p < 0.01 by two-way ANOVA,
followed by Bonferonni post test. See also
Figure S4.
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receptors for Ab oligomers, including a7 nicotinic receptors,
NMDA, mGluR, and AMPA receptors, insulin receptors, PrPc,
and LilrB2/PirB (De Felice et al., 2007, 2009; Kim et al., 2013;
Laure´n et al., 2009; Wang et al., 2000; Zhao et al., 2010).
Although it is possible that Ab oligomers bind to specific cell-
surface proteins such as these and that this stabilizes their
presence on the plasma membrane, the amphipathic hydropho-
bicity of the self-aggregating Ab42 peptide suggests a biochem-
ically more plausible scenario: that the hydrophobic Ab42
oligomers released into the extracellular fluid (ISF) become
rapidly sequestered onto hydrophobic surfaces of adjacent lipid
membranes. Our data here suggest that GM1 ganglioside could
be a principal lipid target of Ab42 oligomers early in the course
of AD-type b-amyloidosis. Gangliosides are particularly en-
riched in the nervous system compared to other tissues, and
the subcellular localization of GM1 has been mapped out to
be mostly in ‘‘raft-like domains’’ enriched in cholesterol and
sphingomyelin on plasma membranes of neuronal processes,
including pre- and postsynaptic membranes, and on certain
lipid vesicles such as exosomes (Hansson et al., 1977; Pernber
et al., 2012; Sonnino et al., 2007; Svennerholm and Gottfries,
1994; The´ry et al., 2009; Yamamoto et al., 2008). Concentra-Neuron 82, 308–tions of GM1 and to a lesser extent
GM2 have been reported to be increased
in detergent-resistant membranes from
frontal cortices of early AD brains
(Molander-Melin et al., 2005) and the
Ab-GM1 complexes were found in the
cortical neuropil and not on amyloid pla-
ques per se in early AD and DS brains(Hayashi et al., 2004). Both our in vivo ISF studies and in vitro
ITC binding data indicate that Ab dimers can rapidly and avidly
associate with GM1-containing lipid membranes. We note that
hydrophobicity alone may not be the key factor for the Ab
oligomers’ preferential binding to GM1, in particular given our
current ITC data and previous in vitro reports that the negatively
charged sialic acid of gangliosides may be a prime binding site
(Ariga et al., 2001; Choo-Smith et al., 1997; McLaurin and Chak-
rabartty, 1996).
Collectively, our results elucidate the complex economy of
newly secreted Ab oligomers as regards their membrane associ-
ation and progressive loss of solubility over time. Our findings
here help explain the apparently very low levels of Ab oligomers
as soluble, freely diffusible species in ISF and CSF at steady
state in vivo, and they support the hypothesis that due to
their increased hydrophobicity, Ab42 oligomers primarily bind
to GM1 ganglioside (and potentially other surface lipids) on
neuronal membranes. Blocking the specific GM1 receptor site
using CTb rescues the well-documented impairment of hippo-
campal LTP by Ab oligomers, suggesting that the binding of Ab
to GM1 may be a step that leads to downstream synaptotoxic
effects of Ab. Thus, Ab, upon binding to GM1 ganglioside, may
then mediate subtle but progressively detrimental biophysical319, April 16, 2014 ª2014 Elsevier Inc. 315
Figure 7. Low Levels of GM1-Bound Ab Are Recovered from hAPP tg Mouse ISF and Human CSF
(A–C) IP: 4396C,WB: CTb for GM1 ganglioside orWB: 3D6+6E10+266+2G3+21F12 for Ab. (A and B) 4396C pull-down of human CSF probed for Ab then stripped
and reprobed for GM1 (A) or GM1 alone on a naive IP blot (B); red asterisk = GM1-Ab. (C) CSF from two humans with differing levels of Ab42 was immuno-
precipitated for GM1-bound Ab. Representative blots of at least three experiments.
(D and E) Levels of GM1-bound Ab recovered using 4396C in ten human CSF samples showed a strong correlation to their levels of Ab42 (D; 21F12/3D6B ELISA)
and less but still significant to levels of Ab40 (E; 2G3/3D6B ELISA).
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Rapid Sequestration of Soluble Ab Oligomers by GM1alterations of neuronal membranes—for e.g., by disrupting
membrane fluidity or ion permeability—and thus lead second-
arily to aberrant function and turnover of a variety of transmem-
brane receptors.
Finally, we show that a GM1-bound Ab species can be
detected, albeit in low amounts, in human CSF and that its
levels are significantly correlated with the levels of Ab42 (and
less so of Ab40). Reduced CSF levels of Ab42 in subjects with
presymptomatic or early AD are a widely validated biomarker
of the disease process, and these levels appear to relate
inversely to amyloid plaque burden, degree of brain atrophy,
and severity of cognitive deficits in humans (Bateman et al.,
2012; Fagan et al., 2009; Motter et al., 1995; Shaw et al.,
2009). Interestingly, there has been a report of increased
GM1 gangliosides in the CSF of AD patients versus healthy
controls (Blennow et al., 1991); however, the level of total
gangliosides may not necessarily reflect the portion of
Ab-bound GM1. Accordingly, it will now be important to
examine whether the GM1-bound Ab complexes in CSF we
describe could serve as an early biomarker in presymptomatic




All animal procedures were approved by the Harvard Medical School Institu-
tional Animal Care and Use Committee. See Supplemental Experimental Pro-
cedures for details.316 Neuron 82, 308–319, April 16, 2014 ª2014 Elsevier Inc.In Vivo Microdialysis
Microdialysis was performed in the hippocampus of awake and normally
behaving mice housed in a ‘‘Raturn’’ cage system (Bioanalytical Systems)
as previously described (Cirrito et al., 2003; Hong et al., 2011). We per-
fused 1.5% bovine serum albumin in artificial CSF (1.3 mM CaCl2, 1.2 mM
MgSO4, 3 mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122 mM
NaCl [pH 7.35]) using BR-2 probes with 35 kDa MWCO membranes (Bio-
analytical Systems) at 0.2 or 0.4 ml/min using an infusion syringe pump
(Stoelting).
Mouse CSF Collection
CSF was collected from cisterna magna of deeply anesthetized mice
(DeMattos et al., 2002). Midline incision was made from top of the skull to dor-
sal thorax, followed by excision of muscles and excess tissue from base of the
skull to first vertebrae. A small hole was made to arachnoid membrane
covering the cistern using tip of 29G one-half inch needle and CSF exiting
compartment was collected using a gel-loading pipet.
Half-Life Studies of Ab in ISF In Vivo
We injected 3 ml of 8 nM Abmonomers or 40 nM dimers into the hippocampus
of adult C57BL6xDBA2 mice through a combination infusion cannula and
microdialysis probe (IBR-2, Bioanalytical Systems) at 0.2 ml/min. ISF was
collected hourly at 0.4 ml/min, paused during the injection, then restarted
1 min after injection. ISF was analyzed for levels of Ab by Ab1-x ELISA or
o-ELISA or for levels of lactate, pyruvate, urea, and glucose (Yale Center for
Clinical Investigation).
Intracortical Injection of Ab
Synthetic Ab or natural Ab isolated fromAD cortex (1–2 ml volume) was injected
at 0.5 ml/min via a Hamilton syringe into left hippocampus of anesthetizedmice
(Hong et al., 2011). Mice were sacrificed <1 min after end of injection for
biochemical analysis.
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Brains were homogenized using a mechanical Dounce homogenizer with 20
strokes at 4,000 rpm in ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl
[pH 7.4]) and protease inhibitors at 4:1 TBS volume:brain wet weight. Homog-
enate was centrifuged for 30 min at 175,000 3 g in a 4C TLA100.2 rotor on
Beckman TL100 (resulting supernatant = ‘‘TBS extract’’). Pellet was homoge-
nized in ice-cold TBS with 1% Triton-X (TBS-Tx) and protease inhibitors at 4:1
TBS-Tx volume:brain wet weight and centrifuged for 30min at 175,0003 g in a
4C TLA100.2 rotor (resulting supernatant = ‘‘TBS-Tx extract’’). TBS-Tx pellet
was incubated with 88% formic acid at RT for 2 hr and lyophilized (‘‘FA
extract’’).
Immunoprecipitation and Western Blot for Ab and GM1 Ganglioside
IP/WB was performed as previously described with minor modifications
(Walsh et al., 2000). See Supplemental Experimental Procedures for details.
Ab ELISA
Sandwich ELISAs for Ab were performed using the MULTI-ARRAY 96-well
Plate platform (MesoScale Discovery) as described previously (Hong et al.,
2011; Yang et al., 2013). See Supplemental Experimental Procedures for
details.
Size-Exclusion Chromatography
ISF sampled at 0.4 ml/min (250 ml) or synthetic Ab (2 ng) were eluted at
0.5 ml/min from a Superdex 75 10/300GL column (GE Healthcare) with
50 mM ammonium acetate (pH 8.5). Resulting 1 ml fractions were lyophilized
and then reconstituted in 60 ml perfusion buffer and analyzed using 6E10 Ab
Triplex ELISA. For WB analysis, samples were subjected to WB using 3D6
and ECL Plus WB Detection Reagent.
Preparation of Ab Isolated from AD Cortex
Ab from TBS extract of human AD cortical tissue was prepared as previously
described (Yang et al., 2013). Briefly, frozen temporal or frontal cortex samples
were dissected and then homogenized as described above for mouse brain
sample preparation. TBS extract was then subjected to IP with 3D6 (Elan,
plc) and the Ab immunoprecipitate was eluted from a Superdex 75 SEC
column in 50 mM ammonium acetate (pH 8.5). The SEC elution profile for Ab
was verified by SDS-PAGE. The corresponding fractions where Ab dimers
were eluted were used for the injection studies.
Isothermal Titration Calorimetry
For ITC, a Microcal ITC-200 instrument with a motor-driven syringe was used.
Volume of the cell was 204 ml. Small volumes of small unilamellar vesicles, ob-
tained by sanitation (40 mM total lipid), were injected into the protein solution
(15 mM) of calorimetry cell at 20C. Buffer used was 25 mM ammonium bicar-
bonate (pH 8.4) with 1 volume % b-mercapto ethanol added in case of the
S26C monomer titrations. Monomeric or dimeric forms of Ab used for experi-
ments were freshly eluted off a Superdex 75 SEC column and the correspond-
ing fractions were kept on ice before use. For the experiments, 19 injections of
2 ml were used, after a preinjection of 0.4 ml to account for diffusion of titrant
from the syringe. Integration of the heat signals and correction of the base
line was done in Microcal Origin 5.0. Control titrations of lipid suspension
into buffer alone were subtracted from the experimental data. The apparent
partition constant was calculated from the initial heat signals where the equi-
librium seems to be independent from electrostatic interaction between the
protein molecules (Seelig, 1997).
Electrophysiology on Acute Hippocampal Slices
Hippocampal slices were prepared as previously described (Li et al., 2013).
Briefly, 350-mm-thick transverse slices from hippocampus of 6- to 8-week-
old C57BL/6x129 were incubated for >90 min in aCSF containing 124 mM
NaCl, 2 mM KCl, 2 mM MgSO4, 1.25 mM NaH2PO4, 2.5 mM CaCl2, 26 mM
NaHCO3, 10 mM D-glucose [pH 7.4], and 310 mM mOsm and then were sub-
merged beneath continuously perfused aCSF saturated with 95% O2 and 5%
CO2 for stimulation at room temperature (24C). For electrophysiology, stan-
dard field excitatory postsynaptic potentials were recorded in the CA1 region
of hippocampus as previously described (Li et al., 2013). Briefly, stimulatingelectrode was placed in Schaffer collaterals to deliver test and conditioning
stimuli, and borosilicate glass recording electrode filled with aCSF was posi-
tioned 200–300 mm from the stimulating electrode in stratum radiatum of
CA1. To induce LTP, we applied two consecutive trains (1 s) of stimuli at
100 Hz separated by 20 s, a protocol that induces LTP lasting 1.5 hr in WT
mice of this genetic background, to the slices. The field potentials were ampli-
fied 1003 using Axon Instruments 200B amplifer and digitized with Digidata
1322A. The data were sampled at 10 kHz and filtered at 2 kHz. Traces were
obtained by pClamp 9.2 and analyzed using the Clampfit 9.2.
Human CSF Samples
CSF samples were provided by Dr. Reisa Sperling (BWH) under institutional re-
view board-approved protocols. Briefly, CSF was collected in polypropylene
tubes using lumbar puncture and then spun at 400 3 g for 10 min; aliquots
of the crystal-clear supernatant were stored at 80C.
Statistical Analysis
Data was analyzed using PRISM (Graphpad Software) for one-way or two-way
ANOVA followed by Bonferroni post hoc test if means were significantly
different by ANOVA, or by two-tailed Student’s t test, as appropriate.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2014.02.027.
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